By binding RANKL with high affinity, which of the following drug reduces bone resorption: (A) Alemtuzumab, (B) Palivizumab, (C) Daclizumab, (D) Denosumab
Answer is D. By binding to RANKL,denosumab inhibitsRANKL from activating its only receptor RANKon the surface of osteoclasts and their precursors. Prevention of RANKL-RANKinteraction inhibits osteoclast formation, function, and survival; thereby decreasing bone resorption and interrupting cancer-induced bone destruction Ref essentials of pharmacology, k. D tripati 5e